Empagliflozin
Embolic Stroke of Undetermined Source
University of East AngliaSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Embolic Stroke of Undetermined Source cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Apixaban University Hospital Tuebingen | Phase 3 | BB |
Acetylsalicylic Acid University Hospital Tuebingen | Phase 3 | BB |
Same molecule, other indications
Empagliflozin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →